Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational... see more

NDAQ:PMN - Post Discussion

ProMIS Neurosciences Inc > Presentation
View:
Post by Trek1701 on Jul 28, 2023 7:25pm

Presentation

The latest corp presentation was recently posted. It includes the Acumen comparisons and data. It also mentions PMN trial data expected to be available mid-2023. The presentation is dated July 2023.

https://d1io3yog0oux5.cloudfront.net/_697be8b01c053496df8401248683965e/promisneurosciences/db/933/8795/pdf/PMN_Corp_Deck_072623.pdf
Comment by G1945V on Jul 29, 2023 6:08am
The Acumen INTERCEPT-AD Clinical Trial Phase 1 took 2 years to complete. Study Start (Actual): 2021-06-21 Study Completion (Actual) 2023-06-12 Is this what we can expect for PMN-310 Clinical Phase 1 Study which has not even started the recruiting? G1945V
Comment by Normandt on Jul 29, 2023 8:58am
Not necessarily. Covid has delayed all clinical trials and treatments in general.
Comment by M101 on Jul 29, 2023 12:58pm
"PMN trial data expected to be available mid-2023. "   Some intern will have to pay for this slip-up, revising history is part of Gail's quality control initiative and this cannot be tolerated. But on the sunny side, any minion downsizing will help to top-up the management's xmas bonus tip jar, asssuming the company is still solvent by then.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities